{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T01:44:29Z","timestamp":1779327869819,"version":"3.51.4"},"reference-count":77,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.acvd.2022.06.003","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T03:33:56Z","timestamp":1662089636000},"page":"529-537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapy"],"prefix":"10.1016","volume":"115","author":[{"given":"Michele","family":"Iavarone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Monda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Vritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimpna","family":"Calila Albert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Verrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Caiazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Lioncino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Amodio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natale","family":"Guarnaccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felice","family":"Gragnano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Bossone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Angela","family":"Losi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Limongelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2022.06.003_bib0390","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2022.06.003_bib0395","first-page":"e558","article-title":"2020 AHA\/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2022.06.003_bib0400","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary artery risk development in (young) adults","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2022.06.003_bib0405","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0410","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijcard.2019.06.073","article-title":"Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy","volume":"299","author":"Limongelli","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0415","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2022.03.050","article-title":"Diagnosis and management of rare cardiomyopathies in adult and paediatric patients. A position paper of the Italian Society of Cardiology (SIC) and Italian Society of Paediatric Cardiology (SICP)","volume":"357","author":"Limongelli","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0420","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.hfc.2021.07.006","article-title":"Cardiovascular involvement in transthyretin cardiac amyloidosis","volume":"18","author":"Lioncino","year":"2022","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.acvd.2022.06.003_bib0425","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.hfc.2021.07.004","article-title":"Hypertrophic cardiomyopathy in rasopathies: diagnosis, clinical characteristics, prognostic implications, and management","volume":"18","author":"Lioncino","year":"2022","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.acvd.2022.06.003_bib0430","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.hfc.2021.07.001","article-title":"Diagnosis and management of cardiovascular involvement in Friedreich Ataxia","volume":"18","author":"Monda","year":"2022","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.acvd.2022.06.003_bib0435","doi-asserted-by":"crossref","first-page":"632293","DOI":"10.3389\/fped.2021.632293","article-title":"Hypertrophic cardiomyopathy in children: Pathophysiology, diagnosis, and treatment of non-sarcomeric causes","volume":"9","author":"Monda","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.acvd.2022.06.003_bib0440","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.hfc.2021.07.005","article-title":"Diagnosis and management of cardiovascular involvement in Fabry disease","volume":"18","author":"Rubino","year":"2022","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.acvd.2022.06.003_bib0445","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.amjcard.2011.12.027","article-title":"Hypertrophic cardiomyopathy with longevity to 90 years or older","volume":"109","author":"Maron","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0450","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijcard.2020.08.054","article-title":"The hospitalizations in hypertrophic cardiomyopathy: \u201cThe dark side of the moon\u201d","volume":"318","author":"Monda","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0455","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.hfc.2021.07.002","article-title":"The risk of sudden unexpected cardiac death in children: Epidemiology, clinical causes, and prevention","volume":"18","author":"Monda","year":"2022","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.acvd.2022.06.003_bib0460","article-title":"Unexplained sudden cardiac arrest in children: clinical and genetic characteristics of survivors","author":"Monda","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0465","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/jamacardio.2015.0354","article-title":"How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: Shaped by 50 Years of clinical research and practice","volume":"1","author":"Maron","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0470","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2020.01.021","article-title":"Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team","volume":"304","author":"Pelliccia","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0475","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4244\/EIJ-D-18-00959","article-title":"Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a contemporary reappraisal","volume":"15","author":"Pelliccia","year":"2019","journal-title":"EuroIntervention"},{"key":"10.1016\/j.acvd.2022.06.003_bib0480","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2022.06.003_bib0485","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0195-668X(03)00479-2","volume":"24","author":"Maron","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2022.06.003_bib0490","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.amjcard.2012.04.051","article-title":"Beta Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy","volume":"110","author":"Nistri","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0495","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijcard.2022.03.013","article-title":"Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study","volume":"354","author":"Monda","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0500","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0505","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1161\/01.CIR.72.4.853","article-title":"Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects","volume":"72","author":"Bonow","year":"1985","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2022.06.003_bib0510","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/01.CIR.64.3.437","article-title":"Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy","volume":"64","author":"Epstein","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2022.06.003_bib0515","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0520","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.105.583500","article-title":"Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy","volume":"114","author":"Harris","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2022.06.003_bib0525","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1093\/eurheartj\/ehq136","article-title":"Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy","volume":"31","author":"Melacini","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2022.06.003_bib0530","first-page":"21","article-title":"Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies","author":"Monda","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.acvd.2022.06.003_bib0535","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.hfc.2021.01.003","article-title":"Combined effect of mediterranean diet and aerobic exercise on weight loss and clinical status in obese symptomatic patients with hypertrophic cardiomyopathy","volume":"17","author":"Limongelli","year":"2021","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.acvd.2022.06.003_bib0540","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jchf.2013.09.001","article-title":"Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy","volume":"1","author":"Shimada","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.acvd.2022.06.003_bib0545","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5339\/gcsp.2015.7","article-title":"INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy-a Randomised Intervention Trial with losartan)","author":"Olivotto","year":"2015","journal-title":"Glob Cardiol Sci Pract"},{"key":"10.1016\/j.acvd.2022.06.003_bib0550","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41591-021-01505-4","article-title":"Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial","volume":"27","author":"Ho","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.acvd.2022.06.003_bib0555","doi-asserted-by":"crossref","first-page":"e004124","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","article-title":"Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: The RESTYLE-HCM randomized, double-blind, placebo-controlled study","volume":"11","author":"Olivotto","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.acvd.2022.06.003_bib0560","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamacardio.2018.4847","article-title":"Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: A randomized clinical trial","volume":"4","author":"Coats","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0565","doi-asserted-by":"crossref","first-page":"e002764","DOI":"10.1161\/CIRCHEARTFAILURE.115.002764","article-title":"Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of late sodium current inhibition on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM) trial","volume":"9","author":"Olivotto","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.acvd.2022.06.003_bib0570","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/2047487320951109","article-title":"Beta-blockers in heart failure prognosis: Lessons learned by MECKI Score Group papers","volume":"27","author":"Cattadori","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0575","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2022.06.003_bib0580","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1177\/2047487319888596","article-title":"Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism","volume":"27","author":"Esposito","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0585","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/heartjnl-2013-304276","article-title":"Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review","volume":"100","author":"Guttmann","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2022.06.003_bib0590","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.117.029267","article-title":"Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy","volume":"136","author":"Rowin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2022.06.003_bib0595","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2022.06.003_bib0600","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ejhf.316","article-title":"Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA)","volume":"17","author":"Guttmann","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2022.06.003_bib0605","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijcard.2017.08.010","article-title":"Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation","volume":"248","author":"Dominguez","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0610","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.chest.2018.11.009","article-title":"Effectiveness and safety of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: A nationwide cohort study","volume":"155","author":"Jung","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.acvd.2022.06.003_bib0615","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","article-title":"Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine","volume":"64","author":"Maron","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0620","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0002-9149(84)80212-X","article-title":"Amiodarone for long-term management of patients with hypertrophic cardiomyopathy","volume":"54","author":"McKenna","year":"1984","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0625","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0735-1097(10)80014-2","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study","volume":"15","author":"Robinson","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0630","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000175883","article-title":"Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy","volume":"82","author":"Tendera","year":"1993","journal-title":"Cardiology"},{"key":"10.1016\/j.acvd.2022.06.003_bib0635","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2022.06.003_bib0640","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/pace.13310","article-title":"Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review","volume":"41","author":"Moore","year":"2018","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0645","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/CIRCEP.113.000339","article-title":"Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term outcomes and mechanisms of arrhythmia recurrence","volume":"6","author":"Santangeli","year":"2013","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0650","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1042\/BST20140324","article-title":"The myosin mesa and a possible unifying hypothesis for the molecular basis of human hypertrophic cardiomyopathy","volume":"43","author":"Spudich","year":"2015","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.acvd.2022.06.003_bib0655","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.acvd.2022.06.003_bib0660","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: A clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.acvd.2022.06.003_bib0665","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of Mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0670","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2022.06.003_bib0675","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of Mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2022.06.003_bib0680","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.echo.2005.05.020","article-title":"Left atrial index is a predictor of exercise capacity in patients with hypertrophic cardiomyopathy","volume":"18","author":"Kjaergaard","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.acvd.2022.06.003_bib0685","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2021.05.007","article-title":"Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy","volume":"239","author":"Desai","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2022.06.003_bib0690","doi-asserted-by":"crossref","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.acvd.2022.06.003_bib0695","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3390\/genes11080947","article-title":"Combined PTPN11 and MYBPC3 Gene mutations in an adult patient with noonan syndrome and hypertrophic cardiomyopathy","volume":"11","author":"Caiazza","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.acvd.2022.06.003_bib0700","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/01.CIR.0000066323.15244.54","article-title":"Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy","volume":"107","author":"Richard","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2022.06.003_bib0705","first-page":"92","article-title":"A complex unit for a complex disease: the HCM-Family Unit","author":"Vriz","year":"2021","journal-title":"Monaldi Arch Chest Dis"},{"key":"10.1016\/j.acvd.2022.06.003_bib0710","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2022.06.003_bib0715","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2022.06.003_bib0720","first-page":"359","article-title":"Gene therapy comes of age","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.acvd.2022.06.003_bib0725","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2022.06.003_bib0730","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1038\/ncomms6515","article-title":"Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice","volume":"5","author":"Mearini","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.acvd.2022.06.003_bib0735","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrd2310","article-title":"Interfering with disease: a progress report on siRNA-based therapeutics","volume":"6","author":"de Fougerolles","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.acvd.2022.06.003_bib0740","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.1236921","article-title":"Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy","volume":"342","author":"Jiang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.acvd.2022.06.003_bib0745","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00424-018-2173-5","article-title":"Gene therapy strategies in the treatment of hypertrophic cardiomyopathy","volume":"471","author":"Prondzynski","year":"2019","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.acvd.2022.06.003_bib0750","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23305","article-title":"Correction of a pathogenic gene mutation in human embryos","volume":"548","author":"Ma","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.acvd.2022.06.003_bib0755","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/nat.2017.0682","article-title":"Development of exon skipping therapies for duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.acvd.2022.06.003_bib0760","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/emmm.201202168","article-title":"Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice","volume":"5","author":"Gedicke-Hornung","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.acvd.2022.06.003_bib0765","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1038\/mtna.2013.31","article-title":"Repair of Mybpc3 mRNA by 5\u2019-trans-splicing in a mouse model of Hypertrophic Cardiomyopathy","volume":"2","author":"Mearini","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.acvd.2022.06.003_bib0770","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.omtn.2017.05.008","article-title":"Evaluation of MYBPC3 trans-splicing and gene replacement as therapeutic options in human iPSC-Derived Cardiomyocytes","volume":"7","author":"Prondzynski","year":"2017","journal-title":"Mol Ther Nucleic Acids"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213622001577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213622001577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:47:58Z","timestamp":1761745678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213622001577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":77,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1875213622001577"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2022.06.003","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapy","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2022.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}